Izraēla - ivrits - Ministry of Health

novartis israel ltd - methotrexate - תרכיז להכנת תמיסה לאינפוזיה - methotrexate 100 mg/ml - methotrexate - methotrexate - antineoplastic chemotherapy: treatment of gestational choriocarcinoma, chorioadenoma destruents and hydatidiform mole. palliation of acute lymphocytic leukemia. in the treatment and prophylaxis of meningeal leukemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukemias in children. in combination with other anticancer agents, methotrexate may be used for the induction of remission, but is most commonly used in maintenance of induced remissions. abitrexate may be used alone or in combination with other antineoplastics in the management of breast cancer, epidermoid cancers of the head and neck, lung cancer (particularly squamous cell and small cell types), bladder cancer and osteogenic cancer. methotrexate is effective in the treatment of the advanced stages (iii and iv peter's staging system) of lymphosarcoma, particularly in children, and in advanced cases of mycosis fungoides. psoriasis: because of the high risk attending its use, methotrexate is indicated only in the

Izraēla - ivrits - Ministry of Health

abic marketing ltd, israel - vinblastine sulfate - תמיסה להזרקה - vinblastine sulfate 1 mg / 1 ml - vinblastine - vinblastine - vinblastine has proved effective in the treatment of the following neoplasms, either alone or in conjunction with other oncolytic drugs:frequently responsive malignancies :• generalized hodgkin's disease (stages iii and iv, ann arbor modification of rye staging system)• non-hodgkin's lymphoma: - reticulum-cell sarcoma - lymphosarcoma• mycosis fungoides.• neuroblastoma.• histiocytosis x.less frequently responsive malignancies :• choriocarcinoma resistant to other chemotherapeutic agents.• embryonal carcinoma of the testis.• carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy.

Izraēla - ivrits - Ministry of Health

megapharm ltd - bleomycin sulfate - אבקה להכנת תמיסה לזריקה - bleomycin sulfate 15000 iu/vial - bleomycin - bleomycin - bleomycin is useful in the management of the following neoplasms: squamous cell carcinoma affecting the mouth, nasopharynx and paranasal sinuses, larynx, oesaphagus, cervix, vagina, penis and skin. well differentiated tumors usually respond better than anaplastic ones.hodgkin's disease and other malignant lymphomas, including mycosis fungoides. testicular carcinoma (seminoma and no seminoma) .malignant effusions of serous cavities (intrapleural and intraperitoneal).secondary indications in which bleomycin has been shown to be of some value include metastatic malignant melanoma, carcinoma of the thyroid lung and bladder. local treatment of refractory warts. bleomycin can be used as a single agent, but is generally used in combination with other cytotoxics and/or with radiation therapy.

Izraēla - ivrits - Ministry of Health

astellas pharma international b.v., israel - tacrolimus - קפסולות - tacrolimus 1 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients.treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.

Izraēla - ivrits - Ministry of Health

astellas pharma international b.v., israel - tacrolimus - קפסולות - tacrolimus 1 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients.treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.

Izraēla - ivrits - Ministry of Health

astellas pharma international b.v., israel - tacrolimus - קפסולות - tacrolimus 5 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients. treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.

Izraēla - ivrits - Ministry of Health

astellas pharma international b.v., israel - tacrolimus - קפסולות - tacrolimus 5 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients. treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.

Izraēla - ivrits - Ministry of Health

astellas pharma international b.v., israel - tacrolimus - קפסולות - tacrolimus 0.5 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients. treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.

Izraēla - ivrits - Ministry of Health

astellas pharma international b.v., israel - tacrolimus - קפסולות - tacrolimus 0.5 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients. treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.

Izraēla - ivrits - Ministry of Health

bristol-myers squibb (israel) limited - belatacept 25 mg/ml - powder for concentrate for infusion - belatacept - nulojix, in combination with corticosteroids and mycophenolic acid (mpa), is indicated for prophylaxis of graft rejection in adults receiving a renal transplant. it is recommended to add an interleukin (il)-2 receptor antagonist for induction therapy to this belatacept-based regimen